Cargando…

Use of anti-Xa factor titration as efficacy marker of enoxaparin in critically ill patients

Detalles Bibliográficos
Autores principales:	Lage, S, Carvalho, R, Kopel, L, Ribeiro, M, Bastos, J, Fagundes Jr, A, Araujo, H, Strunz, C, Garbes-Netto, P
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2006
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4092536/ http://dx.doi.org/10.1186/cc4508

Ejemplares similares

Value of APACHE II score to predict mortality in cardiogenic shock patients of a cardiologic ICU
por: Ribeiro, M, et al.
Publicado: (2006)

Dexmedetomidine for sedation following cardiovascular surgery: a two different loading doses
por: Kopel, L, et al.
Publicado: (2005)

Analysis of central venous catheter-related bloodstream infections in a teaching medical ICU: 2 years of follow-up
por: Kopel, L, et al.
Publicado: (2005)

Antifactor Xa Levels in Critically Ill Korean Patients Receiving Enoxaparin for Thromboprophylaxis: A Prospective Observational Study
por: Lim, So Yeon, et al.
Publicado: (2013)

Anti-activated factor × response to enoxaparin in critically ill patients
por: Einav, S, et al.
Publicado: (2009)

Standard- versus intermediate-dose enoxaparin for anti-factor Xa guided thromboprophylaxis in critically ill patients with COVID-19
por: Hamilton, David Oliver, et al.
Publicado: (2021)

Preliminary report of an enoxaparin dose protocol based on anti-Xa activity in continuous renal replacement therapy
por: Costa, JLF, et al.
Publicado: (2007)

Records of inhospital cardiopulmonary resuscitation in a medical cardiologic ICU
por: Carvalho, RT, et al.
Publicado: (2005)

Trichosporon asahii as an emerging etiologic agent of fungal infection and colonization in heart failure patients in the intensive care unit: epidemiologic characteristics of a 44-patient cohort
por: Carvalho, RT, et al.
Publicado: (2007)

Efficacy and safety of enoxaparin as deep vein thrombosis prophylaxis in critically ill patients
por: Al-Hubail, R, et al.
Publicado: (2012)

Anti-factor Xa Activity Is Not Associated With Venous Thromboembolism in Critically Ill Patients Receiving Enoxaparin for Thromboprophylaxis: A Retrospective Observational Study
por: Dibiasi, Christoph, et al.
Publicado: (2022)

Critically ill patients with edema and ascites may experience subtherapeutic anti-factor Xa levels following abdominal subcutaneous enoxaparin treatment
por: Tharanon, Vichapat, et al.
Publicado: (2022)

Anti-factor Xa levels in obese patients receiving enoxaparin for treatment and prophylaxis indications
por: Tahaineh, Linda, et al.
Publicado: (2018)

742 Evaluation of Anti-Xa Levels and Venous Thromboembolism Prophylaxis with Enoxaparin in Burn Patients
por: Boyd, Allison, et al.
Publicado: (2023)

Pharmacokinetics of enoxaparin in COVID-19 critically ill patients
por: Zufferey, Paul Jacques, et al.
Publicado: (2021)

Results from inhospital cardiopulmonary resuscitation records in a medical cardiologic ICU
por: Timerman, S, et al.
Publicado: (2006)

Optimal Dosing of Enoxaparin in Critically Ill Patients with Venous Thromboembolism
por: Abdulla, Aliya, et al.
Publicado: (2023)

Supratherapeutic anti-factor Xa levels in patients receiving prophylactic doses of enoxaparin: A case series
por: Pannucci, Christopher J., et al.
Publicado: (2016)

Assessment of anti-factor Xa activity of enoxaparin for venous thromboembolism prophylaxis in morbidly obese surgical patients
por: Al Otaib, Nouf, et al.
Publicado: (2017)

Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
por: Zachariah, Seeba, et al.
Publicado: (2020)

Factor Xa Levels in Patients Receiving Prophylactic Enoxaparin Sodium in the Intensive Care Unit of an Academic Hospital
por: Baloo, Mayank M, et al.
Publicado: (2021)

Comparison of Anti-factor Xa Levels in Female and Male Patients with Obesity After Enoxaparin Application for Thromboprophylaxis
por: Wagner, Jonas, et al.
Publicado: (2022)

Anti-Xa Directed Thromboprophylaxis in Critically Ill Patients with Coronavirus Disease 2019
por: Mohamed, Adham, et al.
Publicado: (2022)

Prophylactic anticoagulation with low dose enoxaparin: is the subcutaneous route appropriate in the critically ill?
por: Priglinger, U, et al.
Publicado: (2002)

Clinical experience of prophylactic enoxaparin dosage adjustment guided by AntiXa factor levels in critical care patients with COVID-19-induced pneumonia: observational study()
por: Bermúdez-Ruiz, María del Carmen, et al.
Publicado: (2023)

The effect of a new direct Factor Xa inhibitor on human osteoblasts: an in-vitro study comparing the effect of rivaroxaban with enoxaparin
por: Solayar, Gandhi N, et al.
Publicado: (2011)

An in vitro study to investigate the interference of enoxaparin on plasma levels of direct oral factor Xa inhibitors measured by chromogenic assays
por: Cini, Michela, et al.
Publicado: (2019)

Anti-Xa Activity of Enoxaparin for Prevention of Venous Thromboembolism in Severe Nephrotic Syndrome—A Single Center Prospective Study
por: Matyjek, Anna, et al.
Publicado: (2021)

Procalcitonin: a prognostic marker for critically ill
por: Bhattacharyya, M, et al.
Publicado: (2009)

Effective dosage of enoxaparin for intensive care patients
por: Robinson, S, et al.
Publicado: (2013)

Procalcitonin as a marker of infection in critically ill patients
por: Koukiasa, P, et al.
Publicado: (2004)

Magnesium at admission: is it an outcome marker in the critically ill patient?
por: Passakiotou, M, et al.
Publicado: (2005)

Anti-Factor Xa Levels in Low-weight Surgical Patients Receiving Enoxaparin for Venous Thromboembolism Prophylaxis: A Prospective Cohort Study
por: Hakeam, Hakeam A., et al.
Publicado: (2020)

Effects of dalteparin on anti‐Xa activities cannot be predicted in critically ill COVID‐19 patients
por: van der Heijden, Charlotte D. C. C., et al.
Publicado: (2022)

The right time to measure anti-Xa activity in critical illness: pharmacokinetics of therapeutic dose nadroparin
por: Sytema, Jelmer G., et al.
Publicado: (2023)

Hyperdynamic ejection fraction in the critically ill patient
por: Paonessa, JR, et al.
Publicado: (2014)

Eosinopenia as a marker of sepsis and mortality in critically ill patients
por: Savitskiy, A, et al.
Publicado: (2015)

Anti-Xa activities following 5,000 IU and 7,500 IU of s.c. dalteparin in critically ill patients and 5,000 IU in medical patients: a prospective randomized study
por: Heinz, GH, et al.
Publicado: (2013)

Intensive insulin therapy versus glycemic control in critically ill patients: a prospective controlled trial
por: Azevedo, JR, et al.
Publicado: (2007)

Coagulopathy monitoring and anticoagulation management in COVID-19 patients on ECMO: Advantages of a heparin anti-Xa-based titration strategy
por: Rhoades, Ruben, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u2n7morfk4fvdq16cbkrbpiqhg